$0.24
3.87% day before yesterday
Nasdaq, Dec 27, 10:13 pm CET
ISIN
CA03835T2002
Symbol
APTO
Sector
Industry

Aptose Biosciences Inc. Stock price

$0.24
+0.06 34.64% 1M
-0.51 67.87% 6M
-2.30 90.51% YTD
-2.32 90.59% 1Y
-21.21 98.88% 3Y
-80.01 99.70% 5Y
-87.63 99.73% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.01 3.87%
ISIN
CA03835T2002
Symbol
APTO
Sector
Industry

Key metrics

Market capitalization $14.34m
Enterprise Value $17.10m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-36.20m
Cash position $7.96m
EPS (TTM) EPS $-3.05
Short interest 0.18%

Is Aptose Biosciences Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Aptose Biosciences Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Aptose Biosciences Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Aptose Biosciences Inc.:

Buy
100%

Financial data from Aptose Biosciences Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.43 0.43
7% 7%
-
-0.43 -0.43
7% 7%
-
- Selling and Administrative Expenses 11 11
30% 30%
-
- Research and Development Expense 25 25
28% 28%
-
-36 -36
29% 29%
-
- Depreciation and Amortization 0.43 0.43
7% 7%
-
EBIT (Operating Income) EBIT -36 -36
29% 29%
-
Net Profit -36 -36
27% 27%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aptose Biosciences Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aptose Biosciences Inc. Stock News

Neutral
GlobeNewsWire
9 days ago
SAN DIEGO and TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced that the Nasdaq Hearings Panel (“Panel”) has granted the Company's request for an extension to evidence compliance wit...
Neutral
GlobeNewsWire
17 days ago
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on AML Cells
Neutral
GlobeNewsWire
20 days ago
TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling at U.S. Sites TUS and TUS+VEN Broadly Active Across AML Populations, with Favorable Safety TUS-based therapies are active in FLT3 wildtype, representing ~70% of AML patients TUS Targets VEN Resistance Mechanisms, Enabling TUS+VEN to Achieve Responses in Difficult-to-treat Prior-VEN Failure AML SAN DIEGO and TORO...
More Aptose Biosciences Inc. News

Company Profile

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.

Head office Canada
CEO William Rice
Employees 35
Founded 1986
Website www.aptose.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today